PERAMEDIC is developing a stand-alone drug formulation system for personalised medicine, offering locally prepared, individually customised, segmented release polypills, with an inherently digital technology drive. The system integrates several novel technologies: personal release profiles, in-situ 3D printing of release matrix using adaptive toolpaths, and ultra-precise multichannel powder dosing of drugs into sealed microcompartments.
The PERAMEDIC device will be a tabletop-size pill/capsule printing machine, using canisters of powdered drugs and bioresorbable polymer matrix material. Application scenarios would be first clinical settings, then at later stage, pharmacy locations and medical practices such as GP’s office. For patients, a single pill each day will contain all their medication, complemented by supplements if needed, in quantities and release distributions that are optimised for the individual’s needs and condition.
Personalised drug formulation is a hot topic, but state of the art approaches are limited by low scalability, cost, and regulatory hurdles. Meanwhile, current polypill formulation efforts are hindered by liquid form or hot melt addition approaches, posing stability issues. Due to these difficulties, pill-split grooving is still the prevalent state-of-the-art in individual dosing.
The first development stage towards PERAMEDIC’s breakthrough solution will deliver a lab-scale proof-of-concept prototype system of the functionally combined novel technologies, with tangible preview design of the future technology.
This project has received funding from the European Union’s Horizon Europe Research and Innovation Programme under Grant Agreement No 101130241